Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 2/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 5/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 3/20 | 0.49 |
| ▸ | NPY2R | P49146 | 2/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966543 | 0.97 | CTSK (0.57) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL22117444 | 0.97 | CTSK (0.57) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL5966551 | 0.97 | CTSK (0.57) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL22117445 | 0.97 | CTSK (0.57) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL22117446 | 0.97 | CTSK (0.57) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL22117422 | 0.90 | REN (0.54) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL22117421 | 0.90 | REN (0.54) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL30645707 | 0.90 | CTSS (0.58) | CTSSCTSKNPY4RITGB3ITGA2B | |
| Arginine SCHEMBL28118420 | 0.89 | ACE (0.55) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL23275571 | 0.89 | CTSK (0.59) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092832-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | STEALTH BIOTHERAPEUTICS INC. | 2024-03-21 | — | — | US | disclosed |
| US-20200361987-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | STEALTH BIOTHERAPEUTICS INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092832-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | ABAT, SSBP1, PDF | CTSS 3886/4885CTSK 3009/4885CTSB 3241/4885 |
| US-20200361987-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | ABAT, SSBP1, PDF | CTSS 3886/4885CTSK 3009/4885CTSB 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.